This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collett-Solberg, P. F. Search for Related Content PubMed PubMed Citation Articles by Collett-Solberg, P. F. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology

The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature

Instituto Estadual de Diabetes e Endocrinologia (P.F.C.-S.), Rio de Janeiro, Brazil; and Pediatric Endocrine and Neuroendocrine Units (M.M.), Massachusetts General Hospital, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Paulo Ferrez Collett-Solberg, Rua Saturnino de Brito, 190, Rio de Janeiro, RJ, Brazil 22470–030. E-mail: paulosolberg{at}yahoo.com.

Context: Recombinant human (rh) IGF-I is now available to treat children with short stature resulting from severe primary IGF-I deficiency. This review from the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society discusses different aspects of rhIGF-I therapy, particularly with regard to potential advantages and disadvantages in comparison with the traditional use of rhGH for treatment of short stature.

Evidence Acquisition: We used the Entrez-PubMed search engine to conduct a review of publications addressing IGF-I deficiency, the use of rhIGF-I, and treatment for short stature.

Evidence Synthesis: rhIGF-I, as a twice-daily sc injection, is now approved for treatment of short stature in children with severe primary IGF-I deficiency, which may occur as a consequence of mutations in the GH receptor, defects in the post-GH receptor signaling pathway, and IGF-I gene defects. It is also approved for children with GH deficiency who develop neutralizing antibodies to GH. rhIGF-I significantly improves growth in these conditions. However, adult height may still be suboptimal, possibly due to lack of direct GH effects. Dosing regimens for rhIGF-I administration are under investigation, as are other indications for use of rhIGF-I.

Conclusion: The use of rhIGF-I is justified in conditions approved by the Food and Drug Administration. Until more substantial data become available, the use of rhIGF-I outside Food and Drug Administration recommendations should only be investigational.

This article has been cited by other articles:

				Y. Wu, H. Sun, S. Yakar, and D. LeRoith Elevated Levels of Insulin-Like Growth Factor (IGF)-I in Serum Rescue the Severe Growth Retardation of IGF-I Null Mice Endocrinology, September 1, 2009; 150(9): 4395 - 4403. [Abstract] [Full Text] [PDF]

				T Edouard, S Grunenwald, I Gennero, J P Salles, and M Tauber Prevalence of IGF1 deficiency in prepubertal children with isolated short stature Eur. J. Endocrinol., July 1, 2009; 161(1): 43 - 50. [Abstract] [Full Text] [PDF]